Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
14.68
-0.39 (-2.59%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Immunovant Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Immunovant stock have an average target of 40.14, with a low estimate of 17 and a high estimate of 53. The average target predicts an increase of 173.43% from the current stock price of 14.68.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Immunovant stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 6 | 5 | 3 |
| Buy | 5 | 6 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 12 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy → Hold Downgrades $38 → $17 | Strong Buy → Hold | Downgrades | $38 → $17 | +15.80% | Apr 22, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 20, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $38 → $33 | Strong Buy | Maintains | $38 → $33 | +124.80% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $51 | Strong Buy | Reiterates | $51 | +247.41% | Mar 19, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 10, 2025 |
Financial Forecast
Revenue This Year
1.70B
from 814.35M
Increased by 108.88%
Revenue Next Year
n/a
from 1.70B
EPS This Year
-2.88
from -1.88
EPS Next Year
-3.12
from -2.88
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 123.8M | |||
| Avg | n/a | n/a | 32.5M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.56 | -2.57 | -2.88 | |||
| Avg | -2.88 | -3.12 | -3.28 | |||
| Low | -3.03 | -3.52 | -3.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.